.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Navigating Evolving Therapy Choice in Multiple Myeloma

EP. 1: Smoldering Myeloma: Treatment and Risk Stratification

June 26th 2019

EP. 2: Clinical Trials' Impact on Smoldering Myeloma Management

June 26th 2019

EP. 3: Treating Myeloma: Newly Diagnosed Transplant-Eligible Patients

June 26th 2019

EP. 4: Trial Data in Newly Diagnosed Transplant-Eligible Myeloma

June 26th 2019

EP. 5: Newly Diagnosed Transplant-Eligible Myeloma: The Role of MRD

June 26th 2019

EP. 6: Newly Diagnosed Myeloma: Transplant Ineligibility and Treatment

June 26th 2019

EP. 7: Emerging Therapies for Relapsed/Refractory Multiple Myeloma

June 26th 2019

EP. 8: Subcutaneous Daratumumab in R/R Myeloma: The COLUMBA Trial

June 26th 2019

EP. 9: Venetoclax in Relapsed/Refractory Myeloma: The BELLINI Trial

June 26th 2019

EP. 10: Considering Oral Selinexor for Relapsed/Refractory Myeloma

June 26th 2019

EP. 11: Establishing the Potential of AMG 420 in R/R Multiple Myeloma

June 26th 2019

EP. 12: Considering Other CAR T-Cell Strategies in R/R Myeloma

June 26th 2019

EP. 13: Improving the Future Management of Multiple Myeloma

June 26th 2019